Eupraxia Pharmaceuticals began trading on Nasdaq’s Global Select Market on September 8, 2026, after transferring from the Nasdaq Capital Market. The Toronto listing remains unchanged, and shareholders need no action. Management will also participate in investor conferences on September 11, September 14, and September 15 and 16.

Key Highlights

  • Nasdaq Global Select Market is the exchange’s highest market tier, with financial, Liquidity and governance requirements.
  • Eupraxia management will participate in conferences in New York on September 11, September 14, and September 15 and 16.
  • EP-104GI is in a Phase 1b RESOLVE trial for eosinophilic esophagitis.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) began trading on the Nasdaq Global Select Market on September 8, 2026, after moving from the Nasdaq Capital Market. Its Toronto Stock Exchange listing remains unchanged, and shareholders do not need to take action. Eupraxia’s common shares continue to trade under EPRX. Alex Rothwell, Eupraxia’s chief financial officer, said the move reflects the company’s progress and growth. He said Eupraxia remains focused on advancing its clinical programs and creating long-term value for patients and shareholders.

September Investor Conference Schedule Eupraxia

management will take part in the Cantor Global Healthcare Conference on September 11, 2026, in New York, with a fireside chat and one-on-one meetings. The company will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, also in New York, alongside one-on-one meetings. Management will participate in one-on-one meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 15 and 16, 2026.